Stem definition | Drug id | CAS RN |
---|---|---|
beta-adrenoreceptor antagonists | 520 | 51781-06-7 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 60 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.49 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 88 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
CL (Clearance) | 10.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 4.70 hours | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 10.13 mL/min/kg | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Vd (Volume of distribution) | 4.05 L/kg | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 28, 1988 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Intraocular pressure increased | 67.85 | 34.07 | 14 | 417 | 6064 | 63482527 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hepatitis fulminant | 46.93 | 39.77 | 10 | 277 | 4180 | 34952464 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Intraocular pressure increased | 67.32 | 30.38 | 16 | 755 | 9189 | 79734428 |
Choluria | 30.77 | 30.38 | 5 | 766 | 401 | 79743216 |
Bradycardia | 30.65 | 30.38 | 18 | 753 | 135539 | 79608078 |
None
Source | Code | Description |
---|---|---|
ATC | C07AA15 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, non-selective |
ATC | S01ED05 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Beta blocking agents |
ATC | S01ED55 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Beta blocking agents |
FDA MoA | N0000000161 | Adrenergic beta-Antagonists |
FDA EPC | N0000175556 | beta-Adrenergic Blocker |
CHEBI has role | CHEBI:35530 | beta-adrenergic blockers |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
CHEBI has role | CHEBI:38070 | antiarrhythmic agent |
CHEBI has role | CHEBI:39456 | antiglaucoma agent |
CHEBI has role | CHEBI:66991 | sympatholytic drug |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D018674 | Adrenergic Antagonists |
MeSH PA | D000319 | Adrenergic beta-Antagonists |
MeSH PA | D000889 | Anti-Arrhythmia Agents |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D013565 | Sympatholytics |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Ocular hypertension | indication | 4210003 | DOID:9282 |
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Open-angle glaucoma | indication | 84494001 | DOID:1067 |
Angina pectoris | off-label use | 194828000 | |
Complete atrioventricular block | contraindication | 27885002 | |
Anaphylaxis | contraindication | 39579001 | |
Sinus bradycardia | contraindication | 49710005 | |
Chronic bronchitis | contraindication | 63480004 | DOID:6132 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Heart failure | contraindication | 84114007 | DOID:6000 |
Pulmonary emphysema | contraindication | 87433001 | |
Cardiogenic shock | contraindication | 89138009 | |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Second degree atrioventricular block | contraindication | 195042002 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Pregnancy, function | contraindication | 289908002 | |
Severe chronic obstructive pulmonary disease | contraindication | 313299006 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.31 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | ANTAGONIST | Ki | 9.30 | WOMBAT-PK | CHEMBL | |||
Beta-2 adrenergic receptor | GPCR | ANTAGONIST | Ki | 9.20 | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
4019351 | VUID |
N0000147523 | NUI |
D00599 | KEGG_DRUG |
51781-21-6 | SECONDARY_CAS_RN |
142132 | RXNORM |
C0007299 | UMLSCUI |
CHEBI:3437 | CHEBI |
CHEMBL839 | ChEMBL_ID |
DB00521 | DRUGBANK_ID |
CHEMBL1201002 | ChEMBL_ID |
D002354 | MESH_DESCRIPTOR_UI |
2583 | PUBCHEM_CID |
7142 | IUPHAR_LIGAND_ID |
3990 | INN_ID |
8NF31401XG | UNII |
31453 | MMSL |
4361 | MMSL |
4362 | MMSL |
d00708 | MMSL |
108544005 | SNOMEDCT_US |
386866004 | SNOMEDCT_US |
386867008 | SNOMEDCT_US |
4019351 | VANDF |
4020617 | VANDF |
001863 | NDDF |
004747 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Carteolol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61314-238 | SOLUTION | 10 mg | OPHTHALMIC | ANDA | 19 sections |